JP2016522163A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522163A5
JP2016522163A5 JP2016505495A JP2016505495A JP2016522163A5 JP 2016522163 A5 JP2016522163 A5 JP 2016522163A5 JP 2016505495 A JP2016505495 A JP 2016505495A JP 2016505495 A JP2016505495 A JP 2016505495A JP 2016522163 A5 JP2016522163 A5 JP 2016522163A5
Authority
JP
Japan
Prior art keywords
nrg4
amino acid
acid sequence
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016505495A
Other languages
English (en)
Japanese (ja)
Other versions
JP6565121B2 (ja
JP2016522163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/031171 external-priority patent/WO2014153385A2/en
Publication of JP2016522163A publication Critical patent/JP2016522163A/ja
Publication of JP2016522163A5 publication Critical patent/JP2016522163A5/ja
Application granted granted Critical
Publication of JP6565121B2 publication Critical patent/JP6565121B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016505495A 2013-03-21 2014-03-19 代謝障害を治療する方法 Expired - Fee Related JP6565121B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361804046P 2013-03-21 2013-03-21
US61/804,046 2013-03-21
PCT/US2014/031171 WO2014153385A2 (en) 2013-03-21 2014-03-19 Methods of treating metabolic disorders

Publications (3)

Publication Number Publication Date
JP2016522163A JP2016522163A (ja) 2016-07-28
JP2016522163A5 true JP2016522163A5 (https=) 2017-04-13
JP6565121B2 JP6565121B2 (ja) 2019-08-28

Family

ID=51581794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016505495A Expired - Fee Related JP6565121B2 (ja) 2013-03-21 2014-03-19 代謝障害を治療する方法

Country Status (6)

Country Link
US (1) US9878010B2 (https=)
EP (1) EP2976094B1 (https=)
JP (1) JP6565121B2 (https=)
CN (1) CN105228641A (https=)
ES (1) ES2751391T3 (https=)
WO (1) WO2014153385A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744512B1 (en) 2011-08-15 2019-07-03 Children's Hospital Los Angeles Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
EP3209794A1 (en) * 2014-10-22 2017-08-30 Katholieke Universiteit Leuven KU Leuven Research & Development Modulating adipose tissue and adipogenesis
WO2016116477A1 (en) * 2015-01-20 2016-07-28 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
WO2020086667A1 (en) * 2018-10-25 2020-04-30 American University Method for promoting adipocyte differentiation and obesity-related disease treatment
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN110279860A (zh) * 2019-07-31 2019-09-27 上海交通大学医学院附属瑞金医院 Nrg4作为靶点在制备糖尿病药物中的应用
CN114075272B (zh) * 2020-08-10 2023-09-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
JP2003510029A (ja) * 1999-08-20 2003-03-18 カイロン コーポレイション Ｅｇｆｈ２遺伝子および遺伝子産物
US7094882B2 (en) * 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US6544759B1 (en) * 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
AU2003237367A1 (en) * 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
US20050005622A1 (en) * 2003-07-10 2005-01-13 Powell Brian C. Condiment holder
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
ES2315110B1 (es) * 2006-07-14 2009-12-30 Universidad De Barcelona Compuestos para el tratamiento de enfermedades relacionadas con la resistencia a la insulina.
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management

Similar Documents

Publication Publication Date Title
JP2016522163A5 (https=)
Batt et al. Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension
Zhang et al. A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy
Mulvihill et al. Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat–fed diabetic mice
Lai et al. Atheroprone flow enhances the endothelial-to-mesenchymal transition
Vaverková et al. Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects
WO2003063893B1 (en) Fgfr agonists
US9878010B2 (en) Methods of treating metabolic disorders
Joham et al. Pigment epithelium‐derived factor, insulin sensitivity, and adiposity in polycystic ovary syndrome: impact of exercise training
JP2010520181A5 (https=)
Xu et al. Diet-induced obesity affects muscle regeneration after murine blunt muscle trauma—a broad spectrum analysis
Guo et al. Elevated fibroblast growth factor 23 impairs endothelial function through the NF-κB signaling pathway
Stefanutti et al. Treatment of symptomatic hyperLp (a) lipidemia with LDL-apheresis vs. usual care
Pinti et al. Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease
Lee et al. Correlation of glypican-4 level with basal active glucagon-like peptide 1 level in patients with type 2 diabetes mellitus
US11642395B2 (en) Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
Yeh Cellular senescence and aging.
Hobzová et al. Serum adiponectin level in obstructive sleep apnea: relation of adiponectin to obesity and long-term continuous positive airway pressure therapy
Wolfe et al. Monocytes exposed to plasma from patients with Alzheimer’s disease undergo metabolic reprogramming
JP2021510157A (ja) 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用
Miyata et al. Effects of Valsartan on Fibrinolysis in Hypertensive Patients With Metabolic Syndrome–The KACT-MetS Study–
Onda et al. Causes of death in patients with childhood-onset type 1 diabetes receiving dialysis in Japan: Diabetes Epidemiology Research International (DERI) Mortality Study
Hacıhamdioğlu et al. Elevated urinary T helper 1 chemokine levels in newly diagnosed hypertensive obese children
Hadi et al. Factors associated with nonalcoholic fatty liver disease in individuals with type 2 diabetes
US20230390358A1 (en) Method for alleviating depression using tnfaip3-interacting protein (tnip) 1